Cagent Vascular

Cagent Vascular is a cardiovascular medical device company pioneering Serration Remodeling Therapy (SRT), a novel vessel preparation technology for interventional cardiology and peripheral vascular applications. The company develops and markets the Serranator, a serration balloon catheter designed to gently remodel arteries, reduce recoil, optimize lumen gain, and improve durable outcomes in angioplasty procedures. The Serranator is effective across all lesion morphologies and is marketed as the first and only serration balloon for blood flow restoration. The company conducts clinical studies demonstrating the technology's efficacy, including data on freedom from clinically driven target lesion revascularization (CD-TLR), recoil mitigation compared to plain old balloon angioplasty (POBA), and low bailout stent rates. Recent product expansion includes 7.0 mm and 8.0 mm balloon sizes. Cagent Vascular positions itself as a leader in angioplasty technology, serving interventional cardiologists and vascular specialists treating cardiovascular disease, a leading cause of mortality worldwide. The company maintains active clinical research partnerships with academic medical centers such as Columbia University Medical Center.